Key facts
- Notable investors include Shunwei Capital, Lapam Capital, Fosun Health Capital, Sherpa Healthcare Partners, Wuhan Zhongxin Ruida Investment Management.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Jingrui Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Jingrui Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Jingrui Bio
Provider and developer of drug delivery solutions designed for RNAi (RNA interference). The company focuses on liver- specific drug delivery systems for RNAi therapeutic, enabling clients with drug delivery solutions transfer, consulting, and experimental development, with features including scalable production processes, specialized technical services, and a focus on regulatory-compliant operations.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2023
- Ownership
- Privately Held (backing)
Jingrui Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Jingrui Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Jingrui Bio in its N-PORT filings yet. We sweep new filings monthly.